{"id":"celecoxib-cox-2-inhibitor-oral","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Gastrointestinal upset"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition reduces prostaglandin production, leading to decreased inflammation and pain. Celecoxib's selectivity for COX-2 over COX-1 helps minimize gastrointestinal side effects associated with traditional NSAIDs.","oneSentence":"Celecoxib selectively inhibits COX-2, an enzyme involved in inflammation and pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:50:21.102Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of osteoarthritis, rheumatoid arthritis, and acute pain"},{"name":"Management of primary dysmenorrhea"}]},"trialDetails":[{"nctId":"NCT03912428","phase":"PHASE1","title":"Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions","status":"TERMINATED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2019-06-14","conditions":"Myositis, Inflammatory, Rheumatoid Arthritis","enrollment":31},{"nctId":"NCT07150949","phase":"PHASE2","title":"Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-08-28","conditions":"Locally Advanced Rectal Cancer, Neoadjuvant Therapy","enrollment":138},{"nctId":"NCT04790812","phase":"PHASE4","title":"Preemptive Analgesia With Celecoxib for Acute Dental Pain Management","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-04-22","conditions":"Pain, Postoperative","enrollment":65},{"nctId":"NCT03638297","phase":"PHASE2","title":"PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-08-23","conditions":"Colorectal Cancer","enrollment":29},{"nctId":"NCT04673578","phase":"PHASE2","title":"Adjunctive Celecoxib in Childhood-onset OCD Study","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2021-06-01","conditions":"Obsessive-Compulsive Disorder, Pediatric Psychiatric Disorder","enrollment":80},{"nctId":"NCT00663767","phase":"PHASE2","title":"A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-04-07","conditions":"Dental Pain","enrollment":250},{"nctId":"NCT00075673","phase":"PHASE1","title":"Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2003-11","conditions":"Breast Cancer","enrollment":6},{"nctId":"NCT03185871","phase":"PHASE2","title":"Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2017-09-20","conditions":"Breast Carcinoma","enrollment":""},{"nctId":"NCT03911570","phase":"","title":"Crystalline Glucosamine Sulfate Therapy in Hand Osteoarthritis","status":"COMPLETED","sponsor":"University of Siena","startDate":"2018-09-01","conditions":"Hand Osteoarthritis","enrollment":108},{"nctId":"NCT00061893","phase":"PHASE2","title":"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-04","conditions":"Sarcoma","enrollment":38},{"nctId":"NCT03584074","phase":"PHASE4","title":"Clinical Trial of Pregabalin and COX2 in Spinal Stenosis","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-07-01","conditions":"Spinal Stenosis Lumbar","enrollment":60},{"nctId":"NCT03391570","phase":"NA","title":"Comparing Postoperative Pain Following COX-2 and Prostanoids Expression","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2017-10-17","conditions":"Female Genital Disease","enrollment":60},{"nctId":"NCT00081263","phase":"PHASE2","title":"Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2005-06","conditions":"Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Stage 0 Cervical Cancer","enrollment":130},{"nctId":"NCT02413203","phase":"NA","title":"Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2015-03","conditions":"Healthy","enrollment":20},{"nctId":"NCT02840162","phase":"PHASE2","title":"Pre-Prostatectomy Celecoxib or Placebo","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2001-05","conditions":"Adenocarcinoma of the Prostate, Prostate Cancer","enrollment":34},{"nctId":"NCT00291694","phase":"PHASE2","title":"Protocol for Women at Increased Risk of Developing Breast Cancer","status":"COMPLETED","sponsor":"Carol Fabian, MD","startDate":"2003-04","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT02850211","phase":"PHASE4","title":"A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2011-09","conditions":"Rotator Cuff Tear","enrollment":180},{"nctId":"NCT02790203","phase":"NA","title":"Perioperative Use of a Selective COX2 Inhibitor in Patients Undergoing Elective Colorectal Surgery: the Effect on Post-operative Bowel Motility and Post-operative Pain","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2016-06","conditions":"Prevention of Post Operative Ileus","enrollment":100},{"nctId":"NCT00068770","phase":"PHASE2","title":"Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2003-10","conditions":"Brain and Central Nervous System Tumors","enrollment":35},{"nctId":"NCT02343614","phase":"PHASE2","title":"Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","startDate":"2003-03","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":58},{"nctId":"NCT00314262","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-10","conditions":"Precancerous Conditions","enrollment":17},{"nctId":"NCT00101335","phase":"PHASE2","title":"Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2003-11","conditions":"Head and Neck Cancer, Precancerous Condition","enrollment":""},{"nctId":"NCT00014404","phase":"PHASE2","title":"Celecoxib in Treating Patients With Precancerous Lesions of the Mouth","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-10","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT00300729","phase":"PHASE3","title":"Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy","status":"UNKNOWN","sponsor":"University Hospital, Linkoeping","startDate":"2006-05","conditions":"Non-Small Cell Lung Cancer","enrollment":319}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Celecoxib, COX-2 inhibitor; oral","genericName":"Celecoxib, COX-2 inhibitor; oral","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Celecoxib selectively inhibits COX-2, an enzyme involved in inflammation and pain. Used for Treatment of osteoarthritis, rheumatoid arthritis, and acute pain, Management of primary dysmenorrhea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}